Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action

Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action

Background: Low-dose aspirin’s mechanism of action for preventing colorectal cancer (CRC) is still debated, and the optimal dose remains uncertain. We aimed to optimize the aspirin dose for cancer prevention in CRC patients through deep phenotyping using innovative biomarkers for aspirin’s action.Me...

Full description

Bibliographic Details
Main Authors:	Paola Patrignani, Stefania Tacconelli, Annalisa Contursi, Elena Piazuelo, Annalisa Bruno, Stefania Nobili, Matteo Mazzei, Cristina Milillo, Ulrika Hofling, Gonzalo Hijos-Mallada, Carlos Sostres, Angel Lanas
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Pharmacology
Subjects:	colorectal cancer biomarker-based aspirin dose optimization thromboxane A2 prostaglandin E2 cyclooxygenases platelets
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1362217/full

Similar Items

Characterization of the acetylation of cyclooxygenase-isozymes and targeted lipidomics of eicosanoids in serum and colon cancer cells by the new aspirin formulation IP1867B versus aspirin in vitro
by: Ulrika Hofling, et al.
Published: (2022-12-01)

Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients
by: Angel Lanas, et al.
Published: (2023-04-01)

Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies
by: Patrizia Ballerini, et al.
Published: (2022-03-01)

Aspirin, platelet inhibition and cancer prevention
by: Paola Patrignani, et al.
Published: (2018-11-01)

Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis
by: Gianenrico Rovati, et al.
Published: (2022-02-01)

Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent
by: Paola Patrignani, et al.
Published: (2012-12-01)

Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells
by: Annalisa Contursi, et al.
Published: (2023-01-01)

Antithrombotic Agents and Cancer
by: Annalisa Bruno, et al.
Published: (2018-07-01)

Microfluidic whole blood testing of platelet response to pharmacological agents
by: Ruizhi Li, et al.
Published: (2017-07-01)

Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century
by: Paola Patrignani, et al.
Published: (2010-05-01)

Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System
by: Melania Dovizio, et al.
Published: (2020-12-01)

Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo
by: Luigia Di Francesco, et al.
Published: (2020-04-01)

Aspirin use in obstetrics and gynecology: A comprehensive review of applications and considerations
by: Astrit M. Gashi, et al.
Published: (2023-12-01)

P2Y12 Receptors in Tumorigenesis and Metastasis
by: Patrizia Ballerini, et al.
Published: (2018-02-01)

Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances
by: Steinke JW, et al.
Published: (2016-03-01)

Mechanisms of aspirin-sensitive asthma
by: Sun Ying, et al.
Published: (2004-01-01)

Weight as an assay-independent predictor of poor response to enteric aspirin in cardiovascular patients
by: Meadhbh McCall, et al.
Published: (2020-05-01)

The prevalence and associated factors of aspirin resistance among prophylactic aspirin users
by: Samaneh Ghorbani-Shirkouhi, et al.
Published: (2021-03-01)

Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus
by: Angela Sciacqua, et al.
Published: (2021-06-01)

Blood platelets, prostaglandins and aspirin: a historical and personal rereading
by: Giovanni de Gaetano, et al.
Published: (2024-03-01)

Influence of low‐dose aspirin, resistance exercise, and sex on human skeletal muscle PGE2/COX pathway activity
by: Masatoshi Naruse, et al.
Published: (2021-03-01)

Effect of Prostanoids on Human Platelet Function: An Overview
by: Steffen Braune, et al.
Published: (2020-11-01)

Aspirin Reduces the Potentiating Effect of CD40L on Platelet Aggregation via Inhibition of Myosin Light Chain
by: Kevin Kojok, et al.
Published: (2020-02-01)

The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta
by: Scott W. Walsh, et al.
Published: (2021-06-01)

Aspirin resistance and ischemic heart disease on Iranian experience
by: Masoumeh Sadeghi, et al.
Published: (2012-01-01)

Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?
by: Ilgın Koçak Göktürk, et al.
Published: (2023-03-01)

The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia
by: Sara Alberti, et al.
Published: (2020-12-01)

Should aspirin be replaced with ADP blockers and anti-GPVI to manage thrombosis?
by: Hafsa Khan, et al.
Published: (2023-01-01)

Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome
by: William A.E. Parker, et al.
Published: (2019-02-01)

Prostanoid Metabolites as Biomarkers in Human Disease
by: Helena Idborg, et al.
Published: (2022-08-01)

Prostanoids modulate inflammation and alloimmune responses during graft rejection
by: P.N. Rocha, et al.
Published: (2005-12-01)

Urinary PGE-M in Men with Prostate Cancer
by: Maeve Kiely, et al.
Published: (2021-08-01)

Preeclampsia and aspirin
by: Tae Gyu Ahn, et al.
Published: (2023-05-01)

Effects of chronic low‐dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis
by: Nadine Rohwer, et al.
Published: (2020-04-01)

Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine
by: Davide Serrano, et al.
Published: (2022-03-01)

Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis
by: Mads Lamm Larsen, et al.
Published: (2019-04-01)

Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia
by: Cristina Barale, et al.
Published: (2020-07-01)

Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
by: Kutlwano R. Xulu, et al.
Published: (2022-12-01)

Differential Impact of Serial Measurement of Nonplatelet Thromboxane Generation on Long‐Term Outcome After Cardiac Surgery
by: Nikolaos Kakouros, et al.
Published: (2017-11-01)

Risk Factors for Nonplatelet Thromboxane Generation After Coronary Artery Bypass Graft Surgery
by: Nikolaos Kakouros, et al.
Published: (2016-03-01)